/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The BioHub - by Avetix
  2. Episode 240 - Inder Kaul - CMO at Draig Therapeutics
Episode 240 - Inder Kaul - CMO at Draig Therapeutics

Episode 240 - Inder Kaul - CMO at Draig Therapeutics

The BioHub - by Avetix · Oct 5, 2026

Draig CMO Inder Kaul discusses DT101, a next-gen AMPA modulator targeting fast-acting, durable relief and cognitive gains in MDD.

Parallel Monotherapy and Adjunct Trials Uncouple Pure Efficacy from Real-World Add-On Context

Rather than committing exclusively to monotherapy or adjunctive indications, Draig launched two concurrent Phase 2 studies. A global monotherapy study isolates DT101's dose response without confounding background therapies, confirming biological activity. Simultaneously, a US adjunctive study tests the asset on top of standard antidepressants, matching the commercial standard of care where patients failing frontline generic SSRIs or SNRIs require background combination regimens.

Episode 240 - Inder Kaul - CMO at Draig Therapeutics thumbnail

Episode 240 - Inder Kaul - CMO at Draig Therapeutics

The BioHub - by Avetix·a month ago

Prioritizing Recruitment Speed Over Protocol Spirit Dilutes Patient Quality in MDD Trials

Psychiatric clinical trials often fail due to poorly managed placebo responses and subjective rating endpoints. Inder Kaul argues that rushing enrollment undermines patient quality. Beyond ticking box-checking eligibility criteria, teams must ensure candidates meet the protocol's clinical intent. Additionally, controlling placebo response demands minimizing unnecessary patient burden, selecting sites carefully, and enforcing strict intra- and inter-rater calibration across trial sites.

Episode 240 - Inder Kaul - CMO at Draig Therapeutics thumbnail

Episode 240 - Inder Kaul - CMO at Draig Therapeutics

The BioHub - by Avetix·a month ago

Pulsatile Pharmacokinetics Aligns with Synaptic Plasticity to Accelerate Antidepressant Onset to Day Four

Standard regulatory frameworks recognize fast antidepressant onset within seven days. However, Draig purposefully engineered DT101 with a pulsatile pharmacokinetic profile that allows transient AMPA receptor engagement. Inder Kaul notes this design mechanistically aligns with the synaptic plasticity biology demonstrated by esketamine and psychedelics, aiming to separate from placebo and drive robust, durable antidepressant efficacy as early as day four.

Episode 240 - Inder Kaul - CMO at Draig Therapeutics thumbnail

Episode 240 - Inder Kaul - CMO at Draig Therapeutics

The BioHub - by Avetix·a month ago

Magnetoencephalography in Crossover Phase 1 Trials Solves Psychiatric Functional Pharmacodynamic Biomarker Deficits

Psychiatry drug development routinely suffers from an absence of functional pharmacodynamic biomarkers. Draig addressed this in Phase 1 by implementing magnetoencephalography (MEG) within single- and repeat-dose crossover trial designs. Measuring direct functional brain responses across dose levels within participants boosted assay sensitivity and generated objective pharmacodynamic evidence, which directly informed dose selection for subsequent Phase 2 trials.

Episode 240 - Inder Kaul - CMO at Draig Therapeutics thumbnail

Episode 240 - Inder Kaul - CMO at Draig Therapeutics

The BioHub - by Avetix·a month ago